Literature DB >> 18765737

A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines.

Yuhua Li1, Shifeng Wang, Wei Xin, Giorgio Scarpellini, Zhaoxing Shi, Bronwyn Gunn, Kenneth L Roland, Roy Curtiss.   

Abstract

SopB is a virulence factor of Salmonella encoded by SPI-5. Salmonella sopB deletion mutants are impaired in their ability to cause local inflammatory responses and fluid secretion into the intestinal lumen and also can enhance the immunogenicity of a vectored antigen. In this study, we evaluated the effects on immunogenicity and the efficacy of a sopB deletion mutation on two Salmonella enterica serovar Typhimurium vaccine strains with different attenuating mutations expressing a highly antigenic alpha-helical region of the Streptococcus pneumoniae surface protein PspA from an Asd(+)-balanced lethal plasmid. After oral administration to mice, the two pairs of strains induced high levels of serum antibodies specific for PspA as well as to Salmonella antigens. The levels of antigen-specific serum immunoglobulin G (IgG) and mucosal IgA were higher in mice immunized with sopB mutants. Enzyme-linked immunospot assay results indicated that the spleen cells from mice immunized with a sopB mutant showed higher interleukin-4 and gamma interferon secretion levels than did the mice immunized with the isogenic sopB(+) strain. The sopB mutants also induced higher numbers of CD4(+) CD44(hi) CD62L(hi) and CD8(+) CD44(hi) CD62L(hi) central memory T cells. Eight weeks after primary oral immunization, mice were challenged with 100 50% lethal doses of virulent S. pneumoniae WU2. Immunization with either of the sopB mutant strains led to increased levels of protection compared to that with the isogenic sopB(+) parent. Together, these results demonstrate that the deletion of sopB leads to an overall enhancement of the immunogenicity and efficacy of recombinant attenuated Salmonella vaccine strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765737      PMCID: PMC2573344          DOI: 10.1128/IAI.00720-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  55 in total

Review 1.  Mixed population approach for vaccination with live recombinant Salmonella strains.

Authors:  Z X Yan; T F Meyer
Journal:  J Biotechnol       Date:  1996-01-26       Impact factor: 3.307

Review 2.  Induction of immunoglobulin synthesis by CD4+ T cell clones.

Authors:  R H DeKruyff; L V Rizzo; D T Umetsu
Journal:  Semin Immunol       Date:  1993-12       Impact factor: 11.130

3.  Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.

Authors:  C O Tacket; S M Kelly; F Schödel; G Losonsky; J P Nataro; R Edelman; M M Levine; R Curtiss
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic.

Authors:  R Curtiss; S M Kelly
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

5.  Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.

Authors:  C O Tacket; M B Sztein; G A Losonsky; S S Wasserman; J P Nataro; R Edelman; D Pickard; G Dougan; S N Chatfield; M M Levine
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

6.  Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.

Authors:  E L Hohmann; C A Oletta; S I Miller
Journal:  Vaccine       Date:  1996-01       Impact factor: 3.641

7.  PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice.

Authors:  D E Briles; J D King; M A Gray; L S McDaniel; E Swiatlo; K A Benton
Journal:  Vaccine       Date:  1996-06       Impact factor: 3.641

8.  Salmonella typhimurium induces IFN-gamma production in murine splenocytes. Role of natural killer cells and macrophages.

Authors:  L Ramarathinam; D W Niesel; G R Klimpel
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

9.  Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.

Authors:  C O Tacket; D M Hone; R Curtiss; S M Kelly; G Losonsky; L Guers; A M Harris; R Edelman; M M Levine
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

10.  Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.

Authors:  C O Tacket; G Losonsky; J P Nataro; S J Cryz; R Edelman; A Fasano; J Michalski; J B Kaper; M M Levine
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

View more
  34 in total

1.  Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.

Authors:  Qingke Kong; David A Six; Kenneth L Roland; Qing Liu; Lillian Gu; C Michael Reynolds; Xiaoyuan Wang; Christian R H Raetz; Roy Curtiss
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar typhimurium msbB mutant.

Authors:  Qingke Kong; David A Six; Qing Liu; Lillian Gu; Kenneth L Roland; Christian R H Raetz; Roy Curtiss
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

3.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

4.  Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.

Authors:  Christine G Branger; Wei Sun; Ascención Torres-Escobar; Robert Perry; Kenneth L Roland; Jacqueline Fetherston; Roy Curtiss
Journal:  Vaccine       Date:  2010-10-24       Impact factor: 3.641

5.  Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.

Authors:  Shifeng Wang; Yuhua Li; Huoying Shi; Giorgio Scarpellini; Ascencion Torres-Escobar; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

Review 6.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

7.  Induction of immune responses in mice after oral immunization with recombinant Lactobacillus casei strains expressing enterotoxigenic Escherichia coli F41 fimbrial protein.

Authors:  Jian-Kui Liu; Xi-Lin Hou; Chun-Hua Wei; Li-Yun Yu; Xiao-Jie He; Gui-Hua Wang; Jong-Soo Lee; Chul-Joong Kim
Journal:  Appl Environ Microbiol       Date:  2009-05-15       Impact factor: 4.792

8.  Immunogenicity of a live recombinant Salmonella enterica serovar typhimurium vaccine expressing pspA in neonates and infant mice born from naive and immunized mothers.

Authors:  Huoying Shi; Shifeng Wang; Kenneth L Roland; Bronwyn M Gunn; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2010-01-06

9.  Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice.

Authors:  Huoying Shi; Shifeng Wang; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2013-04-24

10.  Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen.

Authors:  Huoying Shi; Javier Santander; Karen E Brenneman; Soo-Young Wanda; Shifeng Wang; Patti Senechal; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.